An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Completed · Phase 3 · NCT02743494
Conditions: Advanced Cancer
At a glance
- Research payments reported, 2025
- $5,830
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 794
About the trial
- Sponsor
- Bristol-Myers Squibb (with Ono Pharmaceutical Co., Ltd.)
- Tested
- Nivolumab (drug), Placebo (other)
- Dates
- Started 2016-07-14; completion 2024-11-07
- Results posted
- Yes
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
From ClinicalTrials.gov, last updated 2025-11-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $5,830 in research payments for this study in 2025 (6 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sudhir Manda, MD Hematology & Oncology · Tucson, AZ
- Allen L. Cohn, MD Hematology & Oncology · Denver, CO
- Andrew S. Paulson, MD Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rocky Mountain Cancer Centers LLP $2,090
- Arizona Oncology Associates River $1,870
- Texas Onco Southwest Fort Worth $1,870
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.